MiR-29a-3p attenuates hypoxic pulmonary hypertension by inhibiting pulmonary adventitial fibroblast activation

Hypertension

Volumn 65, Issue 2, 2015, Pages 414-420

  Luo, Ying ^a,b,c   Dong, Hai Ying ^b,c   Zhang, Bo ^b,c   Feng, Zhao ^a   Liu, Yi ^b,c   Gao, Yu Qi ^d   Dong, Ming Qing ^a,b,c   Li, Zhi Chao ^a,b,c  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Pathology and Pathophysiology ^*  (China)

^c Lung Injury and Repair Center   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

hypoxia; pulmonary hypertension

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; ENDOTHELIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MICRORNA 29A; MICRORNA 29A 3P; MICRORNA 29B; PARVOVIRUS VECTOR; PLATELET DERIVED GROWTH FACTOR; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; HIF1A PROTEIN, RAT; MADH3 PROTEIN, RAT; MICRORNA; MIRN29 MICRORNA, RAT; SCLEROPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR SECRETION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; HYPOXIA; HYPOXIC PULMONARY HYPERTENSION; LUNG FIBROBLAST; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN PHOSPHORYLATION; PULMONARY ADVENTITIAL FIBROBLAST; PULMONARY HYPERTENSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM; ADVENTITIA; ANIMAL; ANOXIA; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; COMPLICATION; DEPENDOPARVOVIRUS; DRUG EFFECTS; FIBROBLAST; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG; MALE; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT; THERAPEUTIC USE; VASCULAR REMODELING;

ADVENTITIA; ANIMALS; ANOXIA; BASE SEQUENCE; CELLS, CULTURED; DEPENDOVIRUS; DOWN-REGULATION; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG; MALE; MICRORNAS; MOLECULAR SEQUENCE DATA; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SMAD3 PROTEIN; TRANSFECTION; VASCULAR REMODELING;

EID: 84921542435     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04600     Document Type: Article

References (26)

1. Zakynthinos E, Daniil Z, Papanikolaou J, Makris D. Pulmonary hypertension in COPD: pathophysiology and therapeutic targets. Curr Drug Targets. 2011;12:501-513.
2. Bauer NR, Moore TM, McMurtry IF. Rodent models of PAH: are we there yet? Am J Physiol Lung Cell Mol Physiol. 2007;293:L580-L582.
3. Macchia A, Marchioli R, Marfisi R, Scarano M, Levantesi G, Tavazzi L, Tognoni G. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J. 2007;153:1037-1047.
4. Stenmark KR, Yeager ME, El Kasmi KC, Nozik-Grayck E, Gerasimovskaya EV, Li M, Riddle SR, Frid MG. The adventitia: essential regulator of vascular wall structure and function. Annu Rev Physiol. 2013;75:23-47.
5. Stenmark KR, Nozik-Grayck E, Gerasimovskaya E, Anwar A, Li M, Riddle S, Frid M. The adventitia: Essential role in pulmonary vascular remodeling. Compr Physiol. 2011;1:141-161.
6. Wang D, Zhang H, Li M, Frid MG, Flockton AR, McKeon BA, Yeager ME, Fini MA, Morrell NW, Pullamsetti SS, Velegala S, Seeger W, McKinsey TA, Sucharov CC, Stenmark KR. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res. 2014;114:67-78.
7. Stenmark KR, Davie N, Frid M, Gerasimovskaya E, Das M. Role of the adventitia in pulmonary vascular remodeling. Physiology (Bethesda). 2006;21:134-145.
8. Li M, Riddle SR, Frid MG, et al. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunol. 2011;187:2711-2722.
9. He Y, Huang C, Lin X, Li J. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases. Biochimie. 2013;95:1355-1359.
10. Patel V, Noureddine L. MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens. 2012;21:410-416.
11. Cushing L, Kuang PP, Qian J, Shao F, Wu J, Little F, Thannickal VJ, Cardoso WV, Lü J. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45:287-294.
12. Xiao J, Meng XM, Huang XR, Chung AC, Feng YL, Hui DS, Yu CM, Sung JJ, Lan HY. miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Ther. 2012;20:1251-1260.
13. Zhang Y, Huang XR, Wei LH, Chung AC, Yu CM, Lan HY. miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-/Smad3 signaling. Mol Ther. 2014;22:974-985.
14. Qin W, Chung AC, Huang XR, Meng XM, Hui DS, Yu CM, Sung JJ, Lan HY. TGF-/Smad3 signaling promotes renal fibrosis by inhibiting miR-
15. J Am Soc Nephrol. 2011;22:1462-1474.
16. Basu RK, Hubchak S, Hayashida T, Runyan CE, Schumacker PT, Schnaper HW. Interdependence of HIF-1 and TGF-/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression. Am J Physiol Renal Physiol. 2011;300:F898-F905.
17. Zhang H, Akman HO, Smith EL, Zhao J, Murphy-Ullrich JE, Batuman OA. Cellular response to hypoxia involves signaling via Smad proteins. Blood. 2003;101:2253-2260.
18. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res. 2011;157:191-199.
19. Li Y, Kong D, Ahmad A, Bao B, Dyson G, Sarkar FH. Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion. Epigenetics. 2012;7:940-949.
20. Homma N, Morio Y, Takahashi H, Yamamoto A, Suzuki T, Sato K, Muramatsu M, Fukuchi Y. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension. Respiration. 2006;73:105-112.
21. Matori H, Umar S, Nadadur RD, Sharma S, Partow-Navid R, Afkhami M, Amjedi M, Eghbali M. Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. Hypertension. 2012;60:425-430.
22. Kuriyama S, Morio Y, Toba M, Nagaoka T, Takahashi F, Iwakami S, Seyama K, Takahashi K. Genistein attenuates hypoxic pulmonary hypertension via enhanced nitric oxide signaling and the erythropoietin system. Am J Physiol Lung Cell Mol Physiol. 2014;306:L996-L1005.
23. Stenmark KR, Bouchey D, Nemenoff R, Dempsey EC, Das M. Hypoxiainduced pulmonary vascular remodeling: contribution of the adventitial fibroblasts. Physiol Res. 2000;49:503-517.
24. Kang BY, Park KK, Green DE, Bijli KM, Searles CD, Sutliff RL, Hart CM. Hypoxia mediates mutual repression between microRNA-27a and PPAR in the pulmonary vasculature. PLoS One. 2013;8:e79503.
25. Li S, Ran Y, Zhang D, Chen J, Li S, Zhu D. MicroRNA-138 plays a role in hypoxic pulmonary vascular remodelling by targeting Mst1. Biochem J. 2013;452:281-291.
26. Yang S, Banerjee S, Freitas Ad, Cui H, Xie N, Abraham E, Liu G. miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol. 2012;302:L521-L529.